In The Scientist Innovation Spotlight, NervGen’s President & CEO, Mike Kelly, discusses the need for #SCI research, the challenges of nervous system repair, and how our lead drug candidate, NVG-291, aims to break barriers in spinal cord injury treatment.

In The Scientist Innovation Spotlight, NervGen’s President & CEO, Mike Kelly, discusses the need for #SCI research, the challenges of nervous system repair, and how our lead drug candidate, NVG-291, aims to break barriers in spinal cord injury treatment.

Join NervGen Pharma Corp. $NGEN $NGENF management for a virtual investor event on Apr. 9 at 10:00am ET with Drs. Monica Perez & Steven Kirshblum, who’ll discuss the unmet medical need and current treatment landscape for individuals with spinal cord injury. Register: bit.ly/42o06qD

NervGen initiates expanded access policy to allow treatment use of NVG-291 for individuals who’ve participated in NervGen SCI clinical trials & meet specific eligibility criteria after FDA informs expanded access protocol for NVG-291 may proceed. nervgen.com/nervgen-initia… #news

NervGen reports its 2024 year-end financial results and provides business updates. Read the full release here: nervgen.com/nervgen-pharma…

ICYMI: @Nervgen $NGEN $NGENF hosted a virtual investor event with Dr. Perez and Dr. Kirshblum to discuss the unmet medical need and current treatment landscape for individuals with spinal cord injury. Watch here: bit.ly/42o06qD

#Investors: Our President & CEO Mike Kelly will be discussing our work and clinical trial in spinal cord injury at the Bloom Burton & Co. Healthcare Investor Conference. We look forward to connecting on May 5 in Toronto. Learn more: bit.ly/4d0doOZ #BBHIC2025 $NGENF

NervGen announced the results of its Annual General Meeting of Shareholders that was held on May 6, 2025. Read the full release: bit.ly/4jLspXm #Shareholders #announcement #SCI

#NEWS: Today, we reported our Q1 2025 financial results and operational updates. Learn more: bit.ly/Q12025Financia… $NGEN $NGENF #SCI

“This is a tough lifestyle.” - John Ruffolo, Board Member. #DYK there are approx. 18K new #spinalcordinjury cases each year in the U.S.? Learn how we are dedicated to developing neurorestorative therapeutics potentially helping those living with #SCI: bit.ly/NervGenBreakin…

NervGen Chief Medical Officer Dr. Daniel Mikol will present at the upcoming ASIA 2025 Annual Scientific Meeting. Learn more: bit.ly/NervGenPresent… #SCI #clinicaltrial #ASIA2025SCIAnnualMeeting

#DYK: NervGen and Shirley Ryan AbilityLab are conducting a clinical trial in #SCI. Watch to learn more about our unique trial design using electrophysiology. bit.ly/NervGenBreakin… #spinalcordinjury #clinicaltrial #science

NervGen announced the results from the chronic cohort (1-10 years post-injury) of its Phase 1b/2a clinical trial evaluating NVG-291 in spinal cord injury. Read more about the results: bit.ly/1b2aChronicCoh… #SCI #SpinalCordInjury #news

“We achieved our primary endpoint demonstrating improved hand-motor connectivity and showed positive improvement in hand function in the chronic cohort of our Phase 1b/2a trial,” said Mike Kelly, NervGen’s President and Chief Executive Officer. Chief Medical Officer, Dr. Daniel

NervGen announced the appointment of Randall Kaye, MD, to the role of Chief Medical Advisor. Read the full release: nervgen.com/nervgen-announ…… #SCI #SpinalCordInjury #news